Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study

References

• Matthews NH, Li WQ, Qureshi AA. Epidemiology of melanoma. In: Ward WH, Farma JM, editors. Cutaneous Melanoma: Etiology and Therapy. Brisbane (AU): Codon Publications; 12 21, 2017;5–11.
   Google Scholar
• Cavanaugh-Hussey MW, Mu EW, Kang S, Balch CM, Wang T. Older age is associated with a higher incidence of melanoma death but a lower incidence of sentinel lymph node metastasis in the SEER databases (2003–2011). Ann Surg Oncol. 2015;22(7):2120–2126. doi:10.1245/s10434-015-4538-825940571
   PubMed Web of Science ®Google Scholar
• Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622–3634. doi:10.1200/JCO.2001.19.16.362211504744
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–1546. doi:10.1056/NEJMoa191083631562797
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582–588. doi:10.1093/annonc/mdz01130715153
   PubMed Web of Science ®Google Scholar
• Ascierto PA, McArthur GA, Dréno B, et al. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, Phase 3 trial. Lancet Oncol. 2016;17(9):1248–1260. doi:10.1016/S1470-2045(16)30122-X27480103
   PubMed Web of Science ®Google Scholar
• Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381(7):626–636. doi:10.1056/NEJMoa190405931166680
   PubMed Web of Science ®Google Scholar
• Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(10):1315–1327. doi:10.1016/S1470-2045(18)30497-230219628
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714–1768. doi:10.1200/JCO.2017.77.638529442540
   PubMed Web of Science ®Google Scholar
• Klink AJ, Chmielowski B, Feinberg B, Ahsan S, Nero D, Liu FX. Health care resource utilization and costs in first-line treatments for patients with metastatic melanoma in the United States. J Manag Care Spec Pharm. 2019;25(8):869–877. doi:10.18553/jmcp.2019.1844230945965
   PubMed Web of Science ®Google Scholar
• Heinzerling L, Eigentler TK, Fluck M, et al. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open. 2019;4(3):e000491. doi:10.1136/esmoopen-2019-00049131231568
   PubMed Web of Science ®Google Scholar
• Nishijima TF, Muss HB, Shachar SS, Moschos SJ. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis. Cancer Treat Rev. 2016;45:30–37. doi:10.1016/j.ctrv.2016.02.00626946217
   PubMed Web of Science ®Google Scholar
• Ibrahim T, Mateus C, Baz M, Robert C. Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study. Cancer Immunol Immunother. 2018;67(10):1571–1578. doi:10.1007/s00262-018-2219-830056599
   PubMed Web of Science ®Google Scholar
• Larkin J, Del Vecchio M, Ascierto PA, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014;15(4):436–444. doi:10.1016/S1470-2045(14)70051-824582505
   PubMed Web of Science ®Google Scholar
• García-Castaño A, González-Barrallo I, Rubio VEC, et al. 1118P retrospective analysis of safety in elderly BRAF V600 mutation-positive advanced melanoma patients treated with dabrafenib (D) and trametinib (T) and correlation with non-elderly patients. Ann Oncol. 2020;31:S753. doi:10.1016/j.annonc.2020.08.1241
   Web of Science ®Google Scholar
• Chanal J, Kramkimel N, Ratour C, Aractingi S, Guegan S, Avril MF. Pembrolizumab for unresectable or metastatic melanoma in patients older than 85 years of age. Dermatology. 2019;235(3):219–224. doi:10.1159/00049246730721908
   PubMed Web of Science ®Google Scholar
• Wilson RS, Hebert LE, Scherr PA, Dong X, Leurgens SE, Evans DA. Cognitive decline after hospitalization in a community population of older persons. Neurology. 2012;78(13):950–956. doi:10.1212/WNL.0b013e31824d589422442434
   PubMed Web of Science ®Google Scholar
• Meira D, Lavoura P, Ferreira D, et al. Impact of hospitalization in the functionality and quality of life of adults and elderlies. 2015:PA3547.
   Google Scholar
• Fountzilas C, Patel S, Mahalingam D. Review: oncolytic virotherapy, updates and future directions. Oncotarget. 2017;8(60):102617–102639. doi:10.18632/oncotarget.1830929254276
   PubMedGoogle Scholar
• Hu JCC, Coffin RS, Davis CJ, et al. A Phase I Study of OncoVEX GM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 2006;12(22):6737–6747. doi:10.1158/1078-0432.CCR-06-075917121894
   PubMed Web of Science ®Google Scholar
• Andtbacka RHI, Collichio F, Harrington KJ, et al. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. J Immunother Cancer. 2019;7(1):145. doi:10.1186/s40425-019-0623-z31171039
   PubMed Web of Science ®Google Scholar
• Elias R, Karantanos T, Sira E, Hartshorn KL. Immunotherapy comes of age: immune aging & checkpoint inhibitors. J Geriatr Oncol. 2017;8(3):229–235. doi:10.1016/j.jgo.2017.02.00128223073
   PubMed Web of Science ®Google Scholar
• Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117–128. doi:10.1093/jnci/djq49521228314
   PubMed Web of Science ®Google Scholar
• Kandel M, Allayous C, Dalle S, et al. Update of survival and cost of metastatic melanoma with new drugs: estimations from the MelBase cohort. Eur J Cancer. 2018;105:33–40. doi:10.1016/j.ejca.2018.09.02630384014
   PubMed Web of Science ®Google Scholar
• Gorry C, McCullagh L, Barry M. Economic evaluation of systemic treatments for advanced melanoma: a systematic review. Value Health. 2020;23(1):52–60. doi:10.1016/j.jval.2019.07.00331952674
   PubMed Web of Science ®Google Scholar
• Talimogen laherparepvec (Melanom) – nutzenbewertung gemäß § 35a SGB V. 2016. Available from: https://www.g-ba.de/downloads/92-975-1521/2016-06-15_Nutzenbewertung-IQWiG_Talimogen-laherparepvec_D-237.pdf. Accessed 215, 2021.
   Google Scholar
• Imlygic EPAR product information. 2016. Available from: https://www.ema.europa.eu/en/documents/product-information/imlygic-epar-product-information_en.pdf. Accessed 215, 2021.
   Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE v5.0). 2019. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed 210, 2021.
   Google Scholar
• AidKlinik Database 4.9.0. 2021. Accessed 215, 2021.
   Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.02619097774
   PubMed Web of Science ®Google Scholar
• Perez MC, Miura JT, Naqvi SMH, et al. Talimogene laherparepvec (TVEC) for the treatment of advanced melanoma: a single-institution experience. Ann Surg Oncol. 2018;25(13):3960–3965. doi:10.1245/s10434-018-6803-030298318
   PubMed Web of Science ®Google Scholar
• Frohlich A, Niebel D, Fietz S, et al. Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients. Cancer Immunol Immunother. 2020. doi:10.1007/s00262-020-02487-x
   PubMed Web of Science ®Google Scholar
• Zhou AY, Wang DY, McKee S, et al. Correlates of response and outcomes with talimogene laherperpvec. J Surg Oncol. 2019;120(3):558–564. doi:10.1002/jso.2560131264725
   PubMed Web of Science ®Google Scholar
• Bastiaannet E, Battisti N, Loh KP, et al. Immunotherapy and targeted therapies in older patients with advanced melanoma; young International Society of Geriatric Oncology review paper. J Geriatr Oncol. 2019;10(3):389–397. doi:10.1016/j.jgo.2018.06.00930025821
   PubMed Web of Science ®Google Scholar
• Archibald WJ, Victor AI, Strawderman MS, Maggiore RJ. Immune checkpoint inhibitors in older adults with melanoma or cutaneous malignancies: the Wilmot Cancer Institute experience. J Geriatr Oncol. 2020;11(3):496–502. doi:10.1016/j.jgo.2019.07.00531303463
   PubMed Web of Science ®Google Scholar
• Tafinlar: EPAR Product information. Available from: https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf. Accessed 215, 2021.
   Google Scholar
• Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. doi:10.1186/s12877-017-0621-229017448
   PubMed Web of Science ®Google Scholar
• Hakozaki T, Hosomi Y, Shimizu A, Kitadai R, Mirokuji K, Okuma Y. Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy. J Cancer Res Clin Oncol. 2020;146(10):2659–2668. doi:10.1007/s00432-020-03252-432462298
   PubMed Web of Science ®Google Scholar
• Gazze G. Combination therapy for metastatic melanoma: a pharmacist’s role, drug interactions & complementary alternative therapies. Melanoma Manag. 2018;5(2):MMT07. doi:10.2217/mmt-2017-002630459938
   PubMed Web of Science ®Google Scholar
• Diem S, Kasenda B, Martin-Liberal J, et al. Prognostic score for patients with advanced melanoma treated with ipilimumab. Eur J Cancer. 2015;51(18):2785–2791. doi:10.1016/j.ejca.2015.09.00726597444
   PubMed Web of Science ®Google Scholar
• Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol. 2000;18(22):3782–3793. doi:10.1200/JCO.2000.18.22.378211078491
   PubMed Web of Science ®Google Scholar
• Grann AF, Froslev T, Olesen AB, Schmidt H, Lash TL. The impact of comorbidity and stage on prognosis of Danish melanoma patients, 1987–2009: a registry-based cohort study. Br J Cancer. 2013;109(1):265–271. doi:10.1038/bjc.2013.24623681188
   PubMed Web of Science ®Google Scholar
• Fortner BV, Tauer K, Zhu L, et al. Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities. BMC Cancer. 2004;4(1):22. doi:10.1186/1471-2407-4-2215153249
   PubMed Web of Science ®Google Scholar
• Jansen YJL, Rozeman EA, Mason R, et al. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Ann Oncol. 2019;30(7):1154–1161. doi:10.1093/annonc/mdz11030923820
   PubMed Web of Science ®Google Scholar
• Warburton L, Meniawy TM, Calapre L, et al. Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma. Sci Rep. 2020;10(1):18878. doi:10.1038/s41598-020-75837-533139839
   PubMed Web of Science ®Google Scholar
• Long GV, Flaherty KT, Stroyakovskiy D, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017;28(7):1631–1639. doi:10.1093/annonc/mdx17628475671
   PubMed Web of Science ®Google Scholar
• Dutriaux C, Saiag P, Meyer N, et al. Outcomes of elderly treated with pembrolizumab for metastatic melanoma comparing with younger patients. J Clin Oncol. 2018;36(15_suppl):e21508–e21508. doi:10.1200/JCO.2018.36.15_suppl.e21508
   Web of Science ®Google Scholar
• Fleeman N, Bagust A, Boland A, et al. Talimogene laherparepvec for treating metastatic melanoma: an Evidence Review Group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2017;35(10):1035–1046. doi:10.1007/s40273-017-0504-628316007
   PubMed Web of Science ®Google Scholar
• Louie RJ, Perez MC, Jajja MR, et al. Real-world outcomes of talimogene laherparepvec therapy: a multi-institutional experience. J Am Coll Surg. 2019;228(4):644–649. doi:10.1016/j.jamcollsurg.2018.12.02730690076
   PubMed Web of Science ®Google Scholar
• Masoud SJ, Hu JB, Beasley GM, Stewart J, Mosca PJ. Efficacy of talimogene laherparepvec (T-VEC) therapy in patients with in-transit melanoma metastasis decreases with increasing lesion size. Ann Surg Oncol. 2019;26(13):4633–4641. doi:10.1245/s10434-019-07691-331414290
   PubMed Web of Science ®Google Scholar
• Franke V, Berger DMS, Klop WMC, et al. High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a). Int J Cancer. 2019;145(4):974–978. doi:10.1002/ijc.3217230694555
   PubMed Web of Science ®Google Scholar